ANL 16.20 Decreased By ▼ -0.18 (-1.1%)
ASC 14.63 Increased By ▲ 0.95 (6.94%)
ASL 20.04 Decreased By ▼ -0.41 (-2%)
BOP 8.55 Decreased By ▼ -0.05 (-0.58%)
BYCO 7.53 Increased By ▲ 0.24 (3.29%)
FCCL 17.50 Increased By ▲ 0.11 (0.63%)
FFBL 23.15 Increased By ▲ 1.68 (7.82%)
FFL 15.25 Increased By ▲ 0.35 (2.35%)
FNEL 7.35 Increased By ▲ 0.05 (0.68%)
GGGL 17.15 Increased By ▲ 0.74 (4.51%)
GGL 29.95 Increased By ▲ 0.10 (0.34%)
HUMNL 5.96 Increased By ▲ 0.17 (2.94%)
JSCL 20.68 Increased By ▲ 0.28 (1.37%)
KAPCO 28.99 Increased By ▲ 0.31 (1.08%)
KEL 3.48 Increased By ▲ 0.03 (0.87%)
MDTL 2.11 Decreased By ▼ -0.09 (-4.09%)
MLCF 33.60 Increased By ▲ 0.18 (0.54%)
NETSOL 106.00 Decreased By ▼ -1.55 (-1.44%)
PACE 4.33 Decreased By ▼ -0.17 (-3.78%)
PAEL 27.95 Increased By ▲ 0.75 (2.76%)
PIBTL 8.70 Increased By ▲ 0.10 (1.16%)
POWER 6.90 Decreased By ▼ -0.03 (-0.43%)
PRL 17.18 Increased By ▲ 0.87 (5.33%)
PTC 9.30 Increased By ▲ 0.12 (1.31%)
SILK 1.44 No Change ▼ 0.00 (0%)
SNGP 42.33 Increased By ▲ 0.27 (0.64%)
TELE 16.45 Decreased By ▼ -0.09 (-0.54%)
TRG 135.78 Decreased By ▼ -2.22 (-1.61%)
UNITY 29.90 Increased By ▲ 1.40 (4.91%)
WTL 2.40 Decreased By ▼ -0.05 (-2.04%)
BR100 4,668 Increased By ▲ 50.21 (1.09%)
BR30 20,892 Increased By ▲ 107.28 (0.52%)
KSE100 44,822 Increased By ▲ 487.85 (1.1%)
KSE30 17,521 Increased By ▲ 178.45 (1.03%)

Coronavirus
LOW Source: covid.gov.pk
Pakistan Deaths
28,269
1724hr
Pakistan Cases
1,264,384
72024hr
1.61% positivity
Sindh
465,486
Punjab
437,793
Balochistan
33,120
Islamabad
106,445
KPK
176,774
Pakistan

Pakistani pharma in negotiation with Gilead to manufacture COVID-19 drug

BFBL was negotiating for a non-exclusive license agreement with Gilead Sciences Inc to manufacture and sell Remdesi
12 May 2020
  • BFBL was negotiating for a non-exclusive license agreement with Gilead Sciences Inc to manufacture and sell Remdesivir to supply in Pakistan and 126 other countries.

Pakistan pharmaceutical company Ferzsons Laboratories informed that its subsidiary BF Biosciences Ltd (BFBL) was in negotiations with Gilead Sciences Inc for the manufacture and sale of Remdesivir.

In its filing to the Pakistan Stock Exchange (PSX), Ferozsons informed that its listed subsidiary BF Biosciences Limited (BFBL) was negotiating for a non-exclusive license agreement with Gilead Sciences Inc to manufacture and sell Remdesivir to supply in Pakistan and 126 other countries. “There is no obligation at this time for any party to execute any transaction,” Ferozsons told the PSX.

“If an agreement is executed by Gilead and BFBL, once production starts, we are confident that we will have sufficient quantities over time to serve the needs of the patients in Pakistan,” the company added.

“However, at the moment we are uncertain as to the timelines for first launch as an agreement remains to be executed, and thereafter local regulatory approvals and sourcing of Active Pharmaceutical Ingredient for manufacturing Remdesivir may take some time.”

It may be mentioned here that Remdesivir has been approved by the US FDA for the treatment of COVID-19 treatment. “The optimal duration of treatment was under ongoing clinical trials. Under the EUA, both 5-day and 10-day treatment durations have been suggested based on the severity of the disease.”

 

 

 

Comments

Comments are closed.